[go: up one dir, main page]

NO20075648L - Vaksinesammensetning - Google Patents

Vaksinesammensetning

Info

Publication number
NO20075648L
NO20075648L NO20075648A NO20075648A NO20075648L NO 20075648 L NO20075648 L NO 20075648L NO 20075648 A NO20075648 A NO 20075648A NO 20075648 A NO20075648 A NO 20075648A NO 20075648 L NO20075648 L NO 20075648L
Authority
NO
Norway
Prior art keywords
vectors
adenoviruses
hiv
relates
methods
Prior art date
Application number
NO20075648A
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Cathrine Ann Van Wely
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075648(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20075648L publication Critical patent/NO20075648L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse angår virusvektorer omfattende oligonukleotider som koder for HIV-polypeptider, mer spesielt hvor virus-vektoren er et adenovirus. Spesielt er slike adenovirus ikke-humane primat-adenovirus så som simian-adenovirus, mer spesielt sjimpanse-adenovirus. Spesielt angår oppfinnelsen adenovirus-vektorer som omfatter HIV- polynukleotidsekvenser som koder for multiple forskjellige HIV-antigener, for eksempel to eller tre eller flere HIV-antigener. Oppfinnelsen angår videre metoder for fremstilling av virus-vektorer, virus-vektorer produsert ved metodene og anvendelse av vektorene i medisin, spesielt profylaktisk eller terapeutisk vaksinasjon.
NO20075648A 2005-05-12 2007-11-06 Vaksinesammensetning NO20075648L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12
PCT/EP2006/004854 WO2006120034A1 (en) 2005-05-12 2006-05-10 Vaccine composition

Publications (1)

Publication Number Publication Date
NO20075648L true NO20075648L (no) 2008-02-07

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075648A NO20075648L (no) 2005-05-12 2007-11-06 Vaksinesammensetning

Country Status (20)

Country Link
US (1) US20090208515A1 (no)
EP (1) EP1880012B1 (no)
JP (2) JP5175178B2 (no)
KR (1) KR101451620B1 (no)
CN (2) CN103088060A (no)
AR (1) AR053275A1 (no)
AU (1) AU2006245920A1 (no)
BR (1) BRPI0608798A2 (no)
CA (1) CA2608316A1 (no)
EA (1) EA200702190A1 (no)
ES (1) ES2546330T3 (no)
IL (1) IL186828A (no)
MA (1) MA29458B1 (no)
MX (1) MX2007014038A (no)
NO (1) NO20075648L (no)
PE (1) PE20061372A1 (no)
SG (1) SG182173A1 (no)
TW (1) TW200716750A (no)
WO (1) WO2006120034A1 (no)
ZA (1) ZA200709518B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578678B (zh) 2001-11-21 2010-05-26 宾夕法尼亚州立大学托管会 猿猴腺病毒的核酸和氨基酸序列,含有它们的载体以及用法
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US20100055166A1 (en) * 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
KR101662571B1 (ko) * 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
WO2009073104A2 (en) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
SG194079A1 (en) 2011-04-06 2013-11-29 Biovaxim Ltd Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
EP2850194A4 (en) 2012-05-18 2016-06-08 Univ Pennsylvania APE-ADENOVIRES A1302, A1320, A1331 AND A1337 OF THE FAMILY E AND USES THEREOF
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
US10189890B2 (en) * 2013-03-14 2019-01-29 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods
PL3271729T3 (pl) 2015-03-18 2021-05-04 Janssen Vaccines & Prevention B.V. Oznaczenia systemów ekspresji rekombinowanej
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
MX2017016101A (es) * 2015-06-12 2018-02-21 Glaxosmithkline Biologicals Sa Polinucleotidos y polipetidos de adenovirus.
US10343884B2 (en) 2015-07-10 2019-07-09 E. & J. Gallo Winery System and method for dispensing a beverage
ES2829272T3 (es) 2016-05-12 2021-05-31 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018026547A1 (en) 2016-08-01 2018-02-08 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4255397A (en) * 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
EP1320621A4 (en) * 2000-09-15 2005-11-23 Merck & Co Inc IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)
BR0210586A (pt) * 2001-06-22 2005-07-12 Wistar Inst Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas
WO2003025003A2 (en) * 2001-09-20 2003-03-27 Glaxo Group Limited Hiv-gag codon-optimised dna vaccines
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
JP2007534302A (ja) * 2003-09-24 2007-11-29 オクソン セラピュティクス リミテッド Ｈｉｖ医薬
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
IL186828A (en) 2015-06-30
CN101384722A (zh) 2009-03-11
AR053275A1 (es) 2007-04-25
PE20061372A1 (es) 2007-01-16
JP5175178B2 (ja) 2013-04-03
IL186828A0 (en) 2008-02-09
BRPI0608798A2 (pt) 2011-03-15
ES2546330T3 (es) 2015-09-22
ZA200709518B (en) 2014-01-29
KR101451620B1 (ko) 2014-10-21
JP2013046613A (ja) 2013-03-07
WO2006120034A1 (en) 2006-11-16
TW200716750A (en) 2007-05-01
EP1880012A1 (en) 2008-01-23
SG182173A1 (en) 2012-07-30
WO2006120034A8 (en) 2007-11-15
KR20080021659A (ko) 2008-03-07
MX2007014038A (es) 2008-02-11
US20090208515A1 (en) 2009-08-20
MA29458B1 (fr) 2008-05-02
AU2006245920A1 (en) 2006-11-16
CN103088060A (zh) 2013-05-08
JP2008539746A (ja) 2008-11-20
CA2608316A1 (en) 2006-11-16
EA200702190A1 (ru) 2008-04-28
EP1880012B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
NO20075648L (no) Vaksinesammensetning
NO20090194L (no) Rekombinant viral vaksine
Capone et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques
WO2008014521A8 (en) Improved vaccines and methods for using the same
JP2009544333A5 (no)
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
JP2014534202A5 (no)
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RU2019144161A (ru) Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
RU2015135890A (ru) Композиция вакцины
JP2016501015A5 (ja) デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
EA200601043A1 (ru) Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
WO2003076591A8 (en) Compositions and methods for generating an immune response
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
D’Andrea et al. A detailed comparative analysis on the overall codon usage patterns in hepatitis A virus
WO2012042279A3 (en) Viral vector immunogenic compositions
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
NO20045315L (no) Ekspresjon av gener i Modifisert Vacciniavirus Ankara ved a bruke kukoppe ATI-promoteren
WO2007015783A3 (en) Attenuated strains of flaviviruses , and uses thereof
PH12021550785A1 (en) Virus vaccine
WO2010009465A3 (en) Htlv-ii vector and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application